Human serum and urine contain polypeptides which bind mannose 6-phosphate (M6P) and insulin-like growth factor II (IGF II) and crossreact with antibodies against the M6P/IGF II receptor. These polypeptides are considered to be fragments of the M6P/IGF II receptor. The major Mr approx. 205000 fragment in serum and urine is about 10 kDa smaller in size than the membrane-associated receptor and is accompanied by minor forms with Mr values ranging from 104000 to 180000. The presence of receptor fragments in biological fluids indicates that shedding is one of the mechanisms contributing to the turnover of the M6P/IGF II receptor and that receptor fragments are part of the heterogenous group of serum proteins which bind IGF II.
INTRODUCTION
The cation-independent mannose 6-phosphate (M6P) receptor mediates endocytosis of extracellular lysosomal enzymes and transfer of endogenous lysosomal enzymes to lysosomes (for review see von Figura & Hasilik, 1985) .
Several observations suggest that the turnover of this receptor, which exposes more than 90 of its mass at the external side of the membrane (Sahagian & Steer, 1985; Morgan et al., 1987) , occurs via non-lysosomal mechanisms and may involve shedding of receptor fragments (Creek & Sly, 1983; Sahagian, 1984) . Receptor fragments may affect the extracellular lifetime of secreted lysosomal enzymes, if the fragments retain their binding activity. Therefore, we examined biological fluids for the presence of receptor fragments which retain their M6P-binding activity. While this study was in progress, it became apparent that the cation-independent M6P receptor also binds insulinlike growth factor II (IGF II) and is identical with the IGF II receptor (Morgan et al., 1987) .
In the present communication we report the presence of immunoreactive fragments of the M6P/IGF II receptor in human serum and human urine which bind M6P and IGF II.
MATERIALS AND METHODS
Phosphomannan from Hansenula holstii was a gift from Dr M. Slodki (U.S.D.A. Northern Regional Research Center, Peoria, IL, U.S.A.). AH-Sepharose 4B was from Pharmacia. M6P (barium salt) and glucose 6-phosphate (sodium salt) were obtained from Sigma Chemical Co. Bovine serum albumin, Protein A and pnitrophenyl phosphate were purchased from Serva. Disuccinimidyl suberate (DSS) was from Pierce Chemical Co. Auro dye forte was from Janssen Life Science.
Standard proteins for molecular mass determination were purchased from Bio-Rad. Goat anti-(rabbit IgG)-alkaline phosphatase conjugate was from Sigma and TAGO (Burlingame, CA, U.S.A.). Homogeneous 215 kDa M6P/IGF II receptor from human liver and antisera in rabbit or in goat were prepared as described earlier (Geuze et al., 1984) . IgGs were isolated by using Protein A-Sepharose 4B (Pharmacia) and affinitypurified antibodies using receptor-Sepharose 4B (Geuze et al., 1984) . IGF II (preparation II/4 and 1932) was isolated from human serum (Rinderknecht & Humbel, 1976) . IGF II was iodinated with Na125I using the chloramine-T procedure (Zapf et al., 1981) . The specific activity of 1251-IGF II was 150000 c.p.m./ng. Other reagents used in this study were of analytical grade. Protein was determined (Peterson, 1977) using bovine serum albumin as a standard.
Purification of the M6P-receptor fragments from human serum and urine M6P-binding proteins from either source were purified with phosphomannan core-Sepharose 4B affinity matrix (Stein et al., 1987) . In a typical purification procedure 25 ml of human serum or proteins precipitated from 5 litres of human urine with 70 %-saturated (NH4)2SO4
were extensively dialysed against imidazole buffer (50 mM-imidazole, pH 7.0/150 mM-NaCl/ 10 mM-MnCl2/ 5 mM-sodium 8-glycerophosphate/0.05 % Triton X-100). The clear supernatant was passed through the affinity column (15 ml bed vol.). The column was extensively (2-4 litres) washed with the above buffer. The non-specifically bound proteins were eluted with 20 ml of imidazole buffer containing 2 mM-glucose 6-phosphate. Specifically bound proteins were eluted with 20 ml of imidazole buffer containing 2 mM-M6P. The proteins re- Laemmli (1970) . The polypeptides were transferred to nitrocellulose at 10 V/cm for 6 h and characterized by staining with Auro dye forte or with affinity-purified antibodies against the M6P/ IGF II receptor (Conary et al., 1987) . ELISA ELISA was performed as described (Frackelton et al., 1976) with some modification. Wells in microtitre plates were coated for 4 h at 37°C with 50,l of goat antireceptor serum or goat preimmune serum, which were diluted (1:1600) with 25 mM-Tris/HCl (pH 7.0). The wells were saturated with buffer A [5 % (w/v) fat-free milk powder in 50 mM-Tris/HCl (pH 7.8) containing 2 mM-CaCl2/0.05 % Triton X-100/0.02 % sodium azide] overnight. Further coating with serial dilutions ofpurified M6P/IGF II receptor (1.25-20 ng/50 1d) or human serum (diluted in buffer A) was carried out at 37°C for 2 h. The wells were washed with buffer B (50 mM-Tris/ HCI, pH 7.4/0.5 M-NaCl/0.1 % Triton X-100) and saturation with buffer A was repeated for 30 min at 37 'C. Subsequently, affinity-purified rabbit anti-receptor antibodies (1 jug of IgG/ml in buffer A) were added for 2 h at 37 'C. Following the washing with buffer B and saturation with buffer A, the plates were incubated for 2 h with goat anti-(rabbit IgG)-alkaline phosphatase conjugate. The wells were washed with buffer B followed by buffer C (0.1 M-Tris/HCl, pH 9.5/0.1 M-NaCl/2 mMMgCl2). The plate was finally incubated with p-nitrophenyl phosphate (1 mg/ml in buffer C) for 30 min at room temperature and absorbance at 405 nm was recorded.
IGF II binding assay
The binding of receptor with 125I-IGF II was carried out in microtitre plates with some modification of the procedure previously described (Morgan & Roth, 1985) .
Wells were coated with 1 ,tg of Protein A in 50 #1 of 25 mM-Tris/HCl (pH 7.0) for 5 h at 37 'C and were washed five times with 200 #1 of Hepes buffer (50 mMHepes, pH 7.6/150 mM-NaCl/0.1 % Tween 20/0.1 % Triton X-100/0.1 % bovine serum albumin). All following incubations and washings were done with this Hepes buffer. Anti-(receptor IgG), 1.25,g in 25 ,ll, was added to each well. After incubation for 2 h at 37 'C the wells were washed five times, followed by an incubation with purified receptor or receptor fragments for 3 h at 37 'C. After washing five times, 125I-IGF II (20000 c.p.m./well) was added. After incubation for 3 h at room temperature the wells were washed five times, dried, cut, and counted. A control without receptor was performed in each experiment in order to subtract the non-specific binding. with or without 10-6 M-IGF II. Then 125I-IGF II, 13 ,l (250000 c.p.m.), was added and incubated for 3 h at 4 'C. Crosslinking of bound IGF II with receptor was performed with 0.6 mM-DSS in the reaction mixture by incubating for 15 min at 4 'C. The reaction was stopped with 5 ,ul of 1 M-Tris/HCl, pH 7.4, 2.75 ,ul of 20 % SDS and 3 #1 of glycerol (100 %). The reaction mixture was heated at 95 'C for 5 min and the samples were subjected to SDS/polyacrylamide-gel electrophoresis followed by autoradiography. Alternatively the reaction was stopped with 5 u1 of 1 M-Tris/HCl, pH 7.4, and the samples were immunoprecipitated as described .
RESULTS
Immunoreactive fragments of the M6P/IGF II receptor that bind M6P Human serum was passed over a phosphomannan core-Sepharose 4B column. The material eluted from the affinity matrix with glucose 6-phosphate (irrelevant sugar phosphate) and with M6P was concentrated, Serum/urine mannose 6-phosphate/insulin-like growth factor II receptor proteins 797 (Fig. 1, lanes 1 and 2) . In the M6P eluate several polypeptides (Mr 104000 205000) were detectable, which reacted with an affinitypurified antibody against the M6P/IGF II receptor and were absent from the glucose 6-phosphate eluate (Fig. 1,  lanes 3 and 4) . Based on their size, binding and immunological properties, these polypeptides are considered to be fragments of the M6P/IGF II receptor. In different preparations the relative amount of the receptor fragments was subject to some variations (see Fig. 1 , lanes 6-8). The Mr 205000 polypeptide was always the predominant receptor fragment. The purified receptor from human liver has an apparent molecular mass of 215000 (Fig. 1, lane 9) . In human urine the receptor fragments are more homogenous and consist of a major Mr 208000 and a minor Mr 118000 species (Fig. 1, lane 5).
The amount of immunoreactive polypeptides (irrespective of their binding properties) in serum was determined with an ELISA that allowed the detection of > 50 ng of receptor polypeptide/ml of serum. In ten individuals (age 13-70 years) the amount of immunoreactive fragments varied between 1.1 and 1.7 jig of receptor/ml of serum (mean 1.4). The amount of immunoreactive fragments recovered after affinity chromatography accounted for approx. 10%0 of the immunoreactive polypeptides in serum, suggesting that only part of the circulating receptor-related polypeptides retain the M6P-binding site. IGF II binding of receptor fragments
Receptor purified from liver membranes and receptor fragments isolated from serum and urine according to their ability to bind M6P were examined for their ability to bind IGF II. Purified receptor as well as the M6P and glucose 6-phosphate eluates from serum and urine were incubated with 1251I-IGF II, crosslinked and analysed by gel electrophoresis and autoradiography (Fig. 2) . The purified receptor bound 1251-IGF II. The specificity of the binding was demonstrated by the displacement of 1251_ IGF II by an excess of IGF II (Fig. 2, lanes 7 and 8) . The glucose 6-phosphate eluates of serum and urine did not contain IGF II-binding proteins. In the M6P eluates of serum and urine a major Mr 205 000, and a less abundant Mr 185000, IGF 1I-binding polypeptides were found (Fig. 2, lanes 2, 4 and 6 ). It should be noted that crosslinking (independent of IGF II binding) led to aggregation of receptor fragments (Fig. 2, lanes 9 and  10) . The binding of 125I-IGF II to the Mr 205000 and 185 000 polypeptides was inhibited by an excess of IGF II (Fig. 3, lanes 1 and 2) . The relation of the two Vol. 252 IGF IT-binding polypeptides to the M6P/1GF TI receptor is shown by their precipitation with receptor antibodies (Fig. 3, lanes 3-6) . In Figs. 2 and 3 several other polypeptides are seen, which bind '25I-IGF TI. Binding to these polypeptides was not inhibited by an excess of unlabelled IGF II and is therefore considered to be unspecific. Furthermore, these polypeptides are unrelated to the receptor (Fig. 3) and the same IGF TI-binding polypeptides were seen in a control lacking the receptor (not shown). They are likely to be derived from the albumin containing buffer. A solid-phase assay was used to quantify the receptor fragments by virtue of their IGF IT-binding activity. Purified M6P/IGF II receptor was immobilized and incubated with 125I-IGF TI. The amount of bound IGF TI was proportional to the amount of receptor over a range of 2.5-80 ng of receptor protein (Fig. 4) . The glucose 6-phosphate and M6P eluates from human serum were assayed for IGF II binding with the solid-phase assay. IGF TI binding was detectable only in the M6P eluate (Fig. 4 ). An equivalent of 1 ml of serum, which contained 98 ng of immunoreactive material, had the same binding capacity as 26 ng of purified liver receptor.
DISCUSSION
Human serum and human urine contain polypeptides that bind M6P, IGF II and crossreact with antibodies against the M6P/1GF II receptor. These polypeptides are considered to represent extracellular forms of the M6P/IGF II receptor. The major receptor forms in serum and urine are about 10 kDa smaller in size than the intact receptor. The cytosolic and transmembrane domain of the receptor account for about 10 % of its total mass (Morgan et al., 1987) . The major circulating receptor fragment may therefore represent a truncated receptor that has lost its cytosolic and transmembrane domain, but retained most of its extracytosolic portion.
The source of the receptor fragments in serum and urine is not clear. It is conceivable that alternative processing of the receptor mRNA results in formation of truncated receptors, which are secreted due to the lack of a transmembrane domain. The sensitivity of the extracytosolic part of the receptor to proteases, however, renders it likely that the receptor fragments arise from proteolytic cleavage of membrane-associated receptors.
The receptor fragments retaining the M6P-binding site may represent only a subpopulation of the receptor fragments present in biological fluids. This was suggested by the observation that the amount of immunoreactive receptor fragments in serum exceeds the amount of receptor fragments recovered after affinity chromatography by about 10-fold. A similar consideration may apply for the receptor fragments retaining the IGF IIbinding site.
The major Mr 205000 receptor fragment, which was purified on the M6P affinity matrix, had the same size as the major IGF TI-binding receptor fragment. This suggests that the Mr 205000 receptor fragment contains binding sites for both ligands. However, the binding of IGF II and M6P occurs at different sites, since the two ligands do not compete for binding (T. Braulke, unpublished work) . It is therefore conceivable that receptor fragments exist which retain the binding activity for only one type of ligand.
It is obvious from the present results that M6P/IGF II receptor fragments belong to the heterogenous group of IGF IT-binding proteins in serum (for review see Rechler & Nissley, 1985) . Some of these binding proteins are under the control of growth hormone (Moses et al., 1976) . The molecular masses of the binding proteins characterized so far were significantly lower than those of the major receptor fragments (Rechler & Nissley, 1985) . During completion of this manuscript Kiess et al. (1987) reported an Mr approx. 210000 IGF IT-binding protein in rat serum, which crossreacts with antibodies against the IGF II receptor and is approx. 10 kDa smaller than the soluble IGF II receptor from rat placenta membranes. We believe that the IGF II receptor in rat serum corresponds to the major Mr 205000 M6P/IGF IT receptor fragment in human serum and urine.
It has been observed that the half-life of the M6P/IGF II receptor, which is about 1 day in various cultured cells, is not affected by inhibition of lysosomal proteolysis (Creek & Sly, 1983) . This suggested a non-lysosomal pathway for receptor turnover. Chinese hamster ovary cells released immunoreactive receptor fragments if the medium was enriched in lysosomal enzymes (Sahagian, 1984) . The present results suggest that the release of soluble receptor fragments may be a major mechanism determining the turnover of membrane-associated M6P/ IGF II receptors. Receptor fragments that retain their M6P-binding site might bind extracellular lysosomal enzymes. This would prevent the M6P-dependent reuptake of the secreted lysosomal enzymes and prolong their extracellular lifetime. A mechanism allowing proteolytic cleavage of cell-associated receptors concomitant with the secretion of lysosomal enzymes would be particularly suitable for conditions such as tissue repair, inflammation or tumour invasion, where high extracellular concentrations of lysosomal enzymes are found. Limited proteolysis would reduce the probability of reuptake of extracellular lysosomal enzymes in a dual fashion by decreasing the number of endocytotic recep-tors and by masking the M6P-recognition marker on the secreted lysosomal enzymes. This work was supported by the Deutsche Forschungsgemeinschaft (SFB 312), the Fonds der Chemischen Industrie, and by the Swiss National Science Foundation (Grant no. 3.305-0.85 to R. E. H.).
